Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Cited by (363)

Items 301–363 of 363

1. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis
   Dorsey-Treviño, E. G., González-González, J. G., Alvarez-Villalobos, N., González-Nava, V., Contreras-Garza, B. M., Díaz González-Colmenero, A., Rodríguez-Tamez, G., Barrera-Flores, F. J., Farrell, A. M., Montori, V. M. et al. · 2020 · Journal of Endocrinological Investigation
2. Significance of Glycemic Variability in Diabetes Mellitus
   Kusunoki, Yoshiki, Konishi, Kosuke, Tsunoda, Taku, Koyama, Hidenori · 2022 · Internal Medicine
3. Postoperative outcomes among sodium-glucose cotransporter 2 inhibitor users
   Tallarico, Roberta Teixeira, Jing, Bocheng, Lu, Kaiwei, Chawla, Shweta Amy, Luo, Yanting, Badathala, Anusha, Chen, Catherine L., Wallace, Arthur W., Legrand, Matthieu · 2025 · JAMA Surgery
4. Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: A Milestone Achieved
   Sarafidis, Pantelis, Papadopoulos, Christodoulos E., Kamperidis, Vasilios, Giannakoulas, George, Doumas, Michael · 2021 · Hypertension
5. Licogliflozin, a novel SGLT1 and 2 inhibitor: body weight effects in a randomized trial in adults with overweight or obesity
   Bays, Harold E., Kozlovski, Plamen, Shao, Qing, Proot, Pieter, Keefe, Deborah · 2020 · Obesity
6. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: a systematic review and meta-analysis
   Wang, Chen, Zhou, Yue, Kong, Zili, Wang, Xiang, Lv, Wenshan, Geng, Zhuang, Wang, Yangang · 2019 · Diabetes, Obesity and Metabolism
7. An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis
   Balogh, Dora Bianka, Wagner, Laszlo Jozsef, Fekete, Andrea · 2023 · International Journal of Molecular Sciences
8. A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes.
   Yoshida, Yilin, Cheng, Xi, Shao, Hui, Fonseca, Vivian A., Shi, Lizheng · 2020 · Current Diabetes Reports
9. Contemporary trends in the utilization of second‐line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom
   Abrahami, Devin, D'Andrea, Elvira, Yin, Hui, Kim, Seoyoung C., Paik, Julie M., Wexler, Deborah, Azoulay, Laurent, Patorno, Elisabetta · 2023 · Diabetes, Obesity and Metabolism
10. Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial
    Barraclough, Jennifer Y., Yu, Jie, Figtree, Gemma A., Perkovic, Vlado, Heerspink, Hiddo J. L., Neuen, Brendon L., Cannon, Christopher P., Mahaffey, Kenneth W., Schutte, Aletta E., Neal, Bruce et al. · 2022 · Diabetes, Obesity and Metabolism
11. Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
    Cignarella, Andrea, Mioni, Roberto, Sabbadin, Chiara, Dassie, Francesca, Parolin, Matteo, Vettor, Roberto, Barbot, Mattia, Scaroni, Carla · 2020 · International Journal of Molecular Sciences
12. Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis
    Masson, Walter, Lavalle-Cobo, Augusto, Lobo, Martín, Masson, Gerardo, Molinero, Graciela · 2021 · European Journal of Preventive Cardiology
13. Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence
    Khunti, Kamlesh, Aroda, Vanita R., Bhatt, Deepak L., Bozkurt, Biykem, Buse, John B., Heerspink, Hiddo L., Inzucchi, Silvio E., Lam, Carolyn S. P., Marx, Nikolaus, McMurray, John J. V. et al. · 2022 · Diabetes, Obesity and Metabolism
14. Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile
    Muzurović, Emir, Mikhailidis, Dimitri P · 2020 · Expert Opinion on Pharmacotherapy
15. Cost-Effectiveness of canagliflozin added to standard of care for treating diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus (T2DM) in England: estimates using the CREDEM-DKD model
    Willis, Michael, Nilsson, Andreas, Kellerborg, Klas, Ball, Philip, Roe, Rupert, Traina, Shana, Beale, Rebecca, Newell, Isabelle · 2021 · Diabetes Therapy
16. Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
    Pérez-Belmonte, Luis M., Sanz-Cánovas, Jaime, García de Lucas, María D., Ricci, Michele, Avilés-Bueno, Beatriz, Cobos-Palacios, Lidia, Pérez-Velasco, Miguel A., López-Sampalo, Almudena, Bernal-López, M. Rosa, Jansen-Chaparro, Sergio et al. · 2022 · Frontiers in Endocrinology
17. Alternative strategies in cardiac preclinical research and new clinical trial formats
    Kreutzer, Fabian Philipp, Meinecke, Anna, Schmidt, Kevin, Fiedler, Jan, Thum, Thomas · 2022 · Cardiovascular Research
18. Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure
    Cromer, Sara J., Lauffenburger, Julie C., Levin, Raisa, Patorno, Elisabetta · 2023 · Diabetes Care
19. Lifestyle, glycosylated hemoglobin A1c, and survival among patients with stable ischemic heart disease and diabetes
    Mancini, G.B. John, Maron, David J., Hartigan, Pamela M., Spertus, John A., Kostuk, William J., Berman, Daniel S., Teo, Koon K., Weintraub, William S., Boden, William E. · 2019 · Journal of the American College of Cardiology
20. The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: an economic evaluation using data from the DECLARE-TIMI 58 trial
    McEwan, Phil, Morgan, Angharad R., Boyce, Rebecca, Bergenheim, Klas, Gause‐Nilsson, Ingrid A.M., Bhatt, Deepak L., Leiter, Lawrence A., Johansson, Peter A., Mosenzon, Ofri, Cahn, Avivit et al. · 2021 · Diabetes, Obesity and Metabolism
21. Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States
    Zhao, Julie Z., Weinhandl, Eric D., Carlson, Angeline M., St. Peter, Wendy L. · 2023 · Kidney Medicine
22. Should metformin remain first-line medical therapy for patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease? An alternative approach
    Harrington, Josephine L., de Albuquerque Rocha, Natalia, Patel, Kershaw V., Verma, Subodh, McGuire, Darren K. · 2018 · Current Diabetes Reports
23. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
    Gonzalez, Jimmy, Bates, Benjamin A., Setoguchi, Soko, Gerhard, Tobias, Dave, Chintan V. · 2023 · Cardiovascular Diabetology
24. Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
    Weir, Matthew R, Slee, April, Sun, Tao, Balis, Dainius, Oh, Richard, de Zeeuw, Dick, Perkovic, Vlado · 2021 · Clinical Kidney Journal
25. SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors
    Wing, Sara, Ray, Joel G., Yau, Kevin, Jeyakumar, Nivethika, Abdullah, Sheikh, Luo, Bin, Cherney, David Z. I., Harel, Ziv, Hundemer, Gregory L., Mavrakanas, Thomas A. et al. · 2025 · JAMA Internal Medicine
26. Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis
    Rafey, Mohammed Faraz, Butt, Arslan, Coffey, Barry, Reddington, Lisa, Devitt, Aiden, Lappin, David, Finucane, Francis M · 2019 · Endocrinology, Diabetes &amp; Metabolism Case Reports
27. Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications
    Gunawan, Felona, Nassif, Michael E., Partridge, Caitlin, Ahmad, Tariq, Kosiborod, Mikhail, Inzucchi, Silvio E. · 2020 · Cardiovascular Endocrinology &amp; Metabolism
28. Sodium‐Glucose Cotransporter 2 Inhibitors, All‐Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta‐Analysis and Meta‐Regression
    Odutayo, Ayodele, da Costa, Bruno R., Pereira, Tiago V., Garg, Vinay, Iskander, Samir, Roble, Fatimah, Lalji, Rahim, Hincapié, Cesar A., Akingbade, Aquila, Rodrigues, Myanca et al. · 2021 · Journal of the American Heart Association
29. Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes
    Lim, Carl-Emil, Pasternak, Björn, Eliasson, Björn, Ueda, Peter · 2025 · Diabetologia
30. Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States
    Zhao, Julie Z., Weinhandl, Eric D., Carlson, Angeline M., St. Peter, Wendy L. · 2022 · Kidney Medicine
31. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin–angiotensin–aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
    Seidu, Samuel, Kunutsor, Setor K, Topsever, Pinar, Khunti, Kamlesh · 2022 · Endocrinology, Diabetes &amp; Metabolism
32. What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
    Sridhar, Vikas S., Rahman, Habib U., Cherney, David Z.I. · 2020 · Diabetes, Obesity and Metabolism
33. The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome
    Javed, Zeeshan, Papageorgiou, Maria, Madden, Leigh A, Rigby, Alan S, Kilpatrick, Eric S, Atkin, Stephen L, Sathyapalan, Thozhukat · 2020 · Endocrine Connections
34. Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
    Bahtiyar, Gül, Pujals-Kury, Jean, Sacerdote, Alan · 2018 · Current Diabetes Reports
35. Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes
    Goldenberg, Ronald M., Ahooja, Vineeta, Clemens, Kristin K., Gilbert, Jeremy D., Poddar, Megha, Verma, Subodh · 2021 · Canadian Journal of Diabetes
36. Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials
    Qian, B-B., Chen, Q., Li, L., Yan, C-F. · 2020 · Osteoporosis International
37. Cardiovascular risk reduction following metabolic and bariatric surgery.
    Albaugh, Vance L., Kindel, Tammy L., Nissen, Steven E., Aminian, Ali · 2021 · Surgical Clinics of North America
38. Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus
    Fauchier, Laurent, Boriani, Giuseppe, de Groot, Joris R, Kreutz, Reinhold, Rossing, Peter, Camm, A John · 2021 · EP Europace
39. COVID-19 y enfermedad cardiovascular y renal: ¿Dónde estamos? ¿Hacia dónde vamos?
    Pallarés Carratalá, V., Górriz-Zambrano, C., Morillas Ariño, C., Llisterri Caro, J.L., Gorriz, J.L. · 2020 · Medicina de Familia. SEMERGEN
40. The effects of type 1 and type 2 diabetes mellitus on bone health in chronic kidney disease
    Aleksova, Jasna, Ebeling, Peter, Elder, Grahame · 2025 · Nature Reviews Endocrinology
41. Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System
    Luo, Jing, Feldman, Robert, Rothenberger, Scott, Korytkowski, Mary, Fischer, Michael A., Gellad, Walid F. · 2022 · Journal of General Internal Medicine
42. Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches
    Kitada, Munehiro, Hirai, Taro, Koya, Daisuke · 2020 · Diabetology International
43. A Quantitative Systems Pharmacology Kidney Model of Diabetes Associated Renal Hyperfiltration and the Effects of <scp>SGLT</scp> Inhibitors
    Balazki, Pavel, Schaller, Stephan, Eissing, Thomas, Lehr, Thorsten · 2018 · CPT: Pharmacometrics &amp; Systems Pharmacology
44. Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
    Zhao, Li-Min, Zhan, Ze-Lin, Ning, Jie, Qiu, Mei · 2022 · Frontiers in Pharmacology
45. Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations
    Butler, Javed, Anker, Stefan D, Filippatos, Gerasimos, Usman, Muhammad Shariq, Ferreira, Joao Pedro, Zannad, Faiez, Packer, Milton · 2021 · European Heart Journal
46. Cost-effectiveness analysis of initiating type 2 diabetes therapy with a sodium-glucose cotransporter 2 inhibitor versus conventional therapy in Japan
    Igarashi, Ataru, Maruyama-Sakurai, Keiko, Kubota, Anna, Akiyama, Hiroki, Yajima, Toshitaka, Kohsaka, Shun, Miyata, Hiroaki · 2022 · Diabetes Therapy
47. Lipid profile changes associated with SGLT-2 inhibitors and GLP-1 agonists in diabetes and metabolic syndrome
    Premji, Resmi, Nylen, Eric S., Naser, Nejat, Gandhi, Shruti, Burman, Kenneth D., Sen, Sabyasachi · 2022 · Metabolic Syndrome and Related Disorders
48. A systematic review and meta-analysis of the impact of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiovascular outcomes in biologically healthy older adults
    Strain, William D, Griffiths, Jonathan · 2021 · British Journal of Diabetes
49. Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
    Husain, Mansoor, Consoli, Agostino, De Remigis, Alessandra, Pettersson Meyer, Anna Sina, Rasmussen, Søren, Bain, Stephen · 2022 · Cardiovascular Diabetology
50. The peri‐operative implications of sodium‐glucose co‐transporter 2 inhibitors: a narrative review
    Stewart, Paul A., Nestor, Claire C., Clancy, Cillian, Irwin, Michael G. · 2025 · Anaesthesia
51. Lessons from PROMINENT and prospects for pemafibrate
    Fruchart, Jean-Charles, Fruchart-Najib, Jamila, Yamashita, Shizuya, Libby, Peter, Yokote, Koutaro, Kodama, Tatsuhiko, Tomita, Yohei, Ridker, Paul M., Hermans, Michel P., Zambon, Alberto · 2024 · Cardiovascular Diabetology
52. Women and diabetes: preventing heart disease in a new era of therapies
    Galati, Giuseppe, Sabouret, Pierre, Germanova, Olga, Bhatt, Deepak L · 2021 · European Cardiology Review
53. Instituting a successful discharge plan for patients with type 2 diabetes: challenges and solutions
    Demidowich, Andrew P., Batty, Kristine, Zilbermint, Mihail · 2022 · Diabetes Spectrum
54. Effects of newer anti-hyperglycemic agents on cardiovascular outcomes in older adults: systematic review and meta-analysis
    Bilal, Anika, Yi, Fanchao, Gonzalez, Gonzalo Romero, Ali, Mehreen, Im, KyungAh, Ruff, Christian T., Thethi, Tina K., Pratley, Richard E. · 2024 · Journal of Diabetes and its Complications
55. Therapy of Type 2 Diabetes
    Landgraf, Rüdiger, Aberle, Jens, Birkenfeld, Andreas L., Gallwitz, Baptist, Kellerer, Monika, Klein, Harald, Müller-Wieland, Dirk, Nauck, Michael A., Wiesner, Tobias, Siegel, Erhard · 2022 · Experimental and Clinical Endocrinology &amp; Diabetes
56. Racial and regional differences in efficacy of sodium-glucose cotransporter 2 inhibitors on cardiorenal outcomes: a systematic review and meta-analysis
    Kani, Ryoma, Miyamoto, Yoshihisa, Saito, Tetsuya, Watanabe, Atsuyuki, Matsubara, Kyohei, Ejiri, Kentaro, Iwagami, Masao, Slipczuk, Leandro, Hosseini, Kaveh, Fujisaki, Tomohiro et al. · 2025 · International Journal of Cardiology
57. Prevención de ictus en pacientes con diabetes mellitus tipo 2 o prediabetes. Recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología
    Fuentes, B., Amaro, S., Alonso de Leciñana, M., Arenillas, J.F., Ayo-Martín, O., Castellanos, M., Freijo, M., García-Pastor, A., Gomis, M., Gómez Choco, M. et al. · 2021 · Neurología
58. Glucagon-like peptide-1 receptor agonists and cardioprotective benefit in patients with type 2 diabetes without baseline metformin: a systematic review and update meta-analysis
    Lavalle-Cobo, Augusto, Masson, Walter, Lobo, Martín, Masson, Gerardo, Molinero, Graciela · 2021 · High Blood Pressure &amp; Cardiovascular Prevention
59. Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease
    Kugathasan, Luxcia, Aronson, Yarden, Sridhar, Vikas S., Ni, Huajing, Ouimet, Jean-Philippe, Limonte, Christine P., Sarma, Shohinee, Cherney, David Z. I. · 2025 · Expert Review of Clinical Immunology
60. Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016
    Zhao, Julie Z., Weinhandl, Eric D., Carlson, Angeline M., St. Peter, Wendy L. · 2021 · Kidney Medicine
61. Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients
    Zhai, Mike Z., Avorn, Jerry, Liu, Jun, Kesselheim, Aaron S. · 2022 · JAMA Network Open
62. Peripheral Artery Disease and African Americans: Review of the Literature
    Solaru, Khendi White · 2019 · Current Cardiovascular Risk Reports
63. Capillary ketone level and future ketoacidosis risk in patients with type 1 diabetes using sodium-glucose cotransporter inhibitors
    Bapat, Priya, Dhaliwal, Sharon, Song, Cimon, Zhang, Yucheng, Scarr, Daniel, Bakhsh, Abdulmohsen, Budhram, Dalton, Verhoeff, Natasha J., Weisman, Alanna, Fralick, Michael et al. · 2025 · Diabetes Care